# Liposomal Doxorubicin Under Microconfinement and Microscopy

#### 2019.11.05 <u>Kuo-Tang Liao</u>, Craig R. Copeland, Ja Hye Myung, Darby Kozak, Samuel M. Stavis











# Disclaimer

# This presentation reflects the views of the author and should not be construed to represent FDA's views or policies









# **Session Description and Objectives**

- We introduce a method to measure multiple characteristics of particlebased therapeutics, including:
  - Suspension concentration
  - Particle size distribution
  - Encapsulation and dose

- Technical aspects of our work:
  - Device-enhanced optical microscopy
  - Single-particle tracking and sizing
  - Light-scattering and fluorescence
  - Precision, accuracy, and efficiency







# **Biography and Contact Information**

FDA and NIST are working together to develop measurement methods for fundamental study and quality control of particle-based therapeutics

Kuo-Tang Liao

SEG/MND/PML/NISTORS/OGD/CDER/FDAkuo-tang.liao@nist.govkuo-tang.liao@fda.hhs.gov



# **NIST** Measurements of particle-based therapeutics





 $\rightarrow$  Electron microscopy is powerful but not practical for every measurement

Pharm

www.fda.gov

M. Cagdas et al., *Application of Nanotechnology Drug Delivery*, 2014 P. Wibroe et al., *Journal of Controlled Release*, 2016

# NIST Nanoparticle tracking analysis (NTA) in a slit



→ Confinement improves precision of NTA but errors approach 15%

2019 Pharm

www.fda.gov

FDA

C. Haiden et al., Langmuir, 2014, Applied Physics Letters, 2016

# Our idea: NTA in a slit with a pillar array





 $\rightarrow$  Precision, accuracy, efficiency



NIST

K.-T. Liao and C. R. Copeland et al., In preparation, 2019

www.fda.gov

FDA



#### Liposomal doxorubicin under test

Darkfield



150 µm

www.fda.gov

FDA





# Liposomal doxorubicin under test

Darkfield



50 µm

www.fda.gov

FDA





# Liposomal doxorubicin under test

Darkfield after background subtraction



50 µm

www.fda.gov

FDA





### Random walks in two dimensions

FDA

www.fda.gov





# **Aperture array for reference positions**





www.fda.gov



NIST

C. R. Copeland et al., Light: Science & Applications, 2018



# **Pillar array for reference positions**



# Darkfield



150 µm

www.fda.gov



# Accurate tracking and sizing of particles



www.fda.gov

FDA

2019 Pharm Sci 360

NIST

# **Encapsulation and dose measurements**



NIST

2019 Pharm



50 µm

www.fda.gov

FDA

M. Cagdas et al., *Application of Nanotechnology Drug Delivery*, 2014 K.-T. Liao and C. R. Copeland et al., *In preparation*, 2019

# **Acknowledgments**



National Institute of Standards and Technology U.S. Department of Commerce



Craig R. Copeland



Samuel M. Stavis





Ja Hye Myung



Darby Kozak

www.fda.gov

This project was funded by a FDA Nanotechnology Collaborative Opportunities for Research Excellence in Science grant and by an appointment to the Research Participation Program administered by the Oak Ridge Institute for Science



Toward precise, accurate, and efficient measurements of multiple characteristics of particle-based therapeutics

# **Questions?**

Kuo-Tang Liao

SEG/MND/PML/NIST kuo-tang.liao@nist.gov ORS/OGD/CDER/FDA

kuo-tang.liao@fda.hhs.gov



National Institute of Standards and Technology U.S. Department of Commerce FDA U.S. FOOD & DRUG









# NIST Various measurement methods for Doxorubicin

- X- ray Scattering
- Atomic Force Microscopy
- Dynamic Light Scattering
- Nanoparticle Tracking Analysis







## The design of microfluidic device



#### www.fda.gov

FDA



# Inference of liquid media properties

NIST

Pharm



www.fda.gov

FDA

# NIST Uncertainty effect of temperature and viscosity



Pharm

www.fda.gov

# **Mean square displacement (MSD) analysis**





K.-T. Liao and C. R. Copeland et al., In preparation, 2019

www.fda.gov

FDA

# Mean square displacement (MSD) analysis



www.fda.gov

FDA

K.-T. Liao and C. R. Copeland et al., In preparation, 2019

**Pharm** 

### The necessity of widefield calibration

![](_page_24_Figure_1.jpeg)

www.fda.gov

FDA

![](_page_24_Picture_3.jpeg)

C. R. Copeland et al., Light: Science & Applications, 2018

# **NIST** In situ reference material by photon beam

![](_page_25_Picture_1.jpeg)

![](_page_25_Figure_2.jpeg)

![](_page_25_Figure_3.jpeg)

150 µm

www.fda.gov

![](_page_25_Picture_6.jpeg)

### **First function – depth control**

#### $SiO_2$ (20 nm) – Cr (200 nm) hard mask

![](_page_26_Figure_2.jpeg)

 $SF_6 - C_4F_8$  ICP - RIE 2750 W

![](_page_26_Picture_4.jpeg)

K.-T. Liao and C. R. Copeland et al., In preparation, 2019

www.fda.gov

FDA

# **NST** Ex situ scanning probe surface profilometry

![](_page_27_Figure_1.jpeg)

![](_page_27_Figure_2.jpeg)

Etch depth =  $4.871 \,\mu m \pm 0.009 \,\mu m$ 

![](_page_27_Picture_4.jpeg)

K.-T. Liao and C. R. Copeland et al., In preparation, 2019

# **NST** Fluorescence intensity as a probe of slit depth

![](_page_28_Figure_1.jpeg)

K.-T. Liao and C. R. Copeland et al., In preparation, 2019

**Pharm** 

www.fda.gov

FDA

![](_page_29_Figure_0.jpeg)

![](_page_30_Picture_0.jpeg)

## **Representative diameter distribution**

![](_page_30_Picture_2.jpeg)

![](_page_30_Figure_3.jpeg)

#### www.fda.gov

![](_page_30_Picture_5.jpeg)

Y. Barenholz, *Journal of Controlled Release*, 2012 K.-T. Liao and C. R. Copeland et al., *In preparation*, 2019